Penumbra, Inc. (NYSE: PEN) has announced the retirement of Don Kassing from the board of directors, effective April 1, 2025. Kassing has served on the board for 17 years, joining in 2008 and subsequently serving as the presiding director from 2015.
Adam Elsesser, the board chair, president, and CEO of Penumbra, expressed gratitude for Kassing's contributions, particularly highlighting his wisdom and guidance in complex situations and throughout the company's growth phases. Kassing's leadership and dedication to advancing Penumbra's mission were also acknowledged.
Kassing, the president emeritus of San Jose State University, had a distinguished career in higher education and private industry before joining Penumbra's board. He served as president of San Jose State University from 2004 to 2008 and again as interim president from 2010 to 2011. Additionally, he held significant roles at Caleres, Inc. (formerly known as the Brown Group, Inc.) and General Motors Corporation.
Penumbra, Inc., is known as the world's leading thrombectomy company, with a focus on developing innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia. The company's broad portfolio includes computer-assisted vacuum thrombectomy (CAVT), which aims to remove blood clots from head to toe with speed, safety, and simplicity. Penumbra's innovations have been instrumental in supporting healthcare providers, hospitals, and clinics in over 100 countries, ultimately working to improve patient outcomes and quality of life. As a result of these announcements, the company's shares have moved -3.8% on the market, and are now trading at a price of $291.68. For more information, read the company's full 8-K submission here.
